The generation of islet-like endocrine clusters from human pluripotent stem cells (hPSCs) has the potential to provide an unlimited source of insulin-producing β cells for the treatment of diabetes. In order for this cell therapy to become widely adopted, highly functional and well-characterized stem cell-derived islets (SC-islets) need to be manufactured at scale. Furthermore, successful SC-islet replacement strategies should prevent significant cell loss immediately following transplantation and avoid long-term immune rejection. This review highlights the most recent advances in the generation and characterization of highly functional SC-islets as well as strategies to ensure graft viability and safety after transplantation.

Original languageEnglish
Pages (from-to)530-548
Number of pages19
JournalCell Stem Cell
Issue number5
StatePublished - May 4 2023


  • SC-islets
  • bioreactors
  • clinical trials
  • critical quality attributes
  • cryopreservation
  • diabetes
  • differentiation
  • distribution
  • encapsulation
  • immune tolerance
  • insulin
  • pancreas
  • safety
  • scale-up
  • single-cell sequencing
  • stem cells
  • stress
  • therapy
  • transplantation


Dive into the research topics of 'Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes'. Together they form a unique fingerprint.

Cite this